联系客服

000806 深市 *ST银河


首页 公告 ST银河:2021年度财务决算报告

ST银河:2021年度财务决算报告

公告日期:2022-04-30

ST银河:2021年度财务决算报告 PDF查看PDF原文

            北海银河生物产业投资股份有限公司

                  2021 年度财务决算报告

      一、财务报表合并范围

      依据现行会计准则及相关规定,北海银河生物产业投资股份有限公司(以下

  简称“公司”)2021 年度合并财务报表范围主要包括:四川永星电子有限公司、

  南宁银河南方软件有限公司、北海高新技术创业园发展有限公司、南京银河生物

  医药有限公司、南京银河生物技术有限公司、北海银河智汇物业服务有限公司、

  北海星汉企业管理有限公司、成都银河生物医药有限公司。

      二、总体财务分析

      截止 2021 年 12 月 31 日,公司总资产 173,623.10 万元,同比减少 18.36%;

  负债总计 263,110.33 万元,同比增加 27.48% ;归属于母公司股东权益为

  -88,557.50 万元。2021 年度,公司共实现营业收入 114,406.59 万元,同比增加

  3.44%;净利润为亏损 96,847.10 万元,其中归属于母公司所有者的净利润为亏

  损 96,232.45 万元。

      三、主要财务报表项目变动情况

      以下是 2021 年度合并财务报表变动幅度达 30%以上的项目情况表:

                        表 1报表项目变动情况表

                                                                    单位:元人民币

                    期末余额        期初余额        本期增

  项目                            (上期发生                  变动幅度          变动原因

                  (本期发生额)      额)          减变动

交易性金融资产                      24,760,916.25  -24,760,916.25    -100.00%        理财产品赎回

应收票据          113,981,498.04    74,031,088.21  39,950,409.83      53.96%    报告期应收票据增加
应收款项融资                                                                  报告期内银行承兑汇票贴现
                  12,516,542.10    19,246,129.15  -6,729,587.05      -34.97%            增加

预付款项                                                                      原材料紧缺及价格上涨等因
                  53,594,736.60    87,706,284.31  -34,111,547.71    -38.89%    素导致预付款项增加
其他应收款        86,839,063.82    527,530,950.13  -440,691,886.31    -83.54%        债务重组引起

其他流动资产      7,968,693.93      5,547,593.09    2,421,100.84      43.64%      待抵扣进项税增加


  在建工程          7,818,911.85      5,462,069.09    2,356,842.76      43.15%        在建工程增加

  短期借款          43,225,373.78    99,441,841.84  -56,216,468.06    -56.53%      债务重组后减少

  预收款项          3,013,936.81      1,428,702.06    1,585,234.75      110.96%        预收租金增加

  合同负债          116,874,232.32    68,729,831.33  48,144,400.99      70.05%  收到的合同预收款项增加
  应交税费                                                                      应付增值税、企业所得税增
                    28,680,873.19    20,635,867.99    8,045,005.20      38.99%            加

  其他流动负债      15,098,713.08    308,753,034.48  -293,654,321.40    -95.11%      债务重组后减少

  长期借款                                                                      长期借款转一年内到期流动
                                      59,000,000.00  -59,000,000.00    -100.00%            负债

  预计负债                                                                      对已判决的诉讼计提相关损
                  1,773,757,639.75  818,518,068.89  955,239,570.86    116.70%            失

  递延所得税负债                                                                投资性房地产公允价值变动
                    4,499,742.69      2,867,392.25    1,632,350.44      56.93%          影响税负

  其他综合收益                                                                  股票出售及股票公允价值增
                    -3,449,439.02    -29,782,692.36  26,333,253.34      88.42%          加部分

 管理费用                                                                      报告期咨询费、职工五险一
                    183,157,737.23    121,807,959.45  61,349,777.78      50.37%      金及诉讼费增加

 研发费用            58,974,712.20    34,642,205.02  24,332,507.18      70.24%    报告期研发投入增加
其他收益            15,295,608.12    51,530,586.56  -36,234,978.44    -70.32%  上年债务重组其他收益较大
投资收益            -664,610.43      -2,721,036.91    2,056,426.48      75.58%  长期股权投资收益变动影响
公允价值变动收益                                                                受投资性房地产公允价值变
                    6,529,401.75      3,519,916.25    3,009,485.50      85.50%          动影响

信用减值损失                                                                    对已判决的诉讼计提相关损
                    -973,905,421.45    -7,594,920.85  -966,310,500.60  -12723.11%            失

资产减值损失        -3,773,326.30      636,218.52    -4,409,544.82    -693.09%    固定资产减值损失增加
资产处置收益        -634,947.57      566,042.83    -1,200,990.40    -212.17%      固定资产处置影响

营业外收入          2,407,367.76      4,640,434.81    -2,233,067.05      -48.12%    营业外收入较上年少
营业外支出          33,677,017.70    77,209,151.45  -43,532,133.75    -56.38%    利息违约金较上年减少
 所得税费用                                                                    本期子公司盈利计提所得税
                    35,479,820.73    21,112,123.24  14,367,697.49      68.05%          费用增加

        四、主要财务指标


                  表 2  主要财务指标表

资产负债率        151.54%    负债总额/资产总额

流动比率          141.37%    流动资产总额/流动负债总额

速动比率          99.66%      (流动资产总额-存货-预付账款)/流动负债

                              总额

净资产收益率      不适用      净利润/平均净资产

                              北海银河生物产业投资股份有限公司
                                        董  事  会

                                    二〇二二年四月二十九日

[点击查看PDF原文]